Back

EVOLUTION-HF DEallEF: a non-interventional study program of patients with heart failure and initiated on dapagliflozin: results of 1st interim analysis

1 September 2025 (13:15 - 14:00)
Organised by: Logo
Congress Presentation Part of: Heart failure in the real world Pharmacotherapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Professor Matthias Paul

Muenster (Germany)

7 More presentations in this session

Presentation thumbnail
Real-world treatment patterns in newly diagnosed heart failure patients stratified by ejection fraction subtype in Japan
Doctor R. Knapp (Berlin, DE)
Abstract Slides Video
Presentation thumbnail
Association between calcium channel blockers prescription and outcome according to left ventricular ejection fraction: data from a real-world heart failure population
Doctor M. Gori (Bergamo, IT)
Abstract Slides Video
Presentation thumbnail
Outpatient diuretic use in patients with baroreflex activation therapy
Doctor L. Straw (Columbia, US)
Abstract Slides Video
Presentation thumbnail
Active vs passive best-practice alerts to improve guideline-directed lipid-lowering therapy intensification in patients with recent myocardial infarction and elevated LDL-C
Doctor D. Karalis (Philadelphia, US)
Abstract Slides Video
Presentation thumbnail
Prognostic impact of maximum vasodilation therapy in heart failure
Doctor C. Santos Aragao (Aracaju, BR)
Abstract Slides Video

Access the full session

Session thumbnail
Heart failure in the real world

The Event

Event poster

ESC Congress 2025

1 September 2025 13:15 CET
You may be interested in
thumbnail
Congress Presentation
Clinical characteristics and treatment patterns of new users of dapagliflozin for heart failure with reduced ejection fraction: an observational study programme across 12 countries (EVOLUTION HF)
thumbnail
Congress Presentation
Characteristics of patients initiating dapagliflozin for heart failure with reduced ejection fraction in Italian clinical practice: a 6-month interim analysis of EVOLUTION-HF Italy
thumbnail
Congress Presentation
Dapagliflozin for heart failure with reduced ejection fraction: early experience of treatment adherence and impact on patient-reported outcomes in EVOLUTION HF, a multinational, observational study

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources